Hologic Inc Stock Price, News & Analysis

Hologic, Inc. (Nasdaq: HOLX) has launched its innovative Genius™ Digital Diagnostics System in Europe, enhancing cervical cancer screening with artificial intelligence and advanced imaging. This system aims to identify pre-cancerous lesions and cervical cancer cells more effectively. The Genius system is designed to improve lab efficiency and workflow while promoting collaboration among laboratories. Customer feedback has been overwhelmingly positive, highlighting its potential to transform screening processes and enhance patient outcomes.

Hologic, Inc. (NASDAQ: HOLX) is set to launch the NovaSure® V5 global endometrial ablation device at the AAGL 50th Global Congress (November 14-17). This innovative device, building on a 20-year legacy of the NovaSure system, aims to enhance the physician experience. With over 3 million treatments performed since its FDA approval in 2001, the device incorporates advanced features like the EndoForm™ cervical seal technology and SureClear™ fluid removal system. The launch reflects Hologic's commitment to improving outcomes for women and providing physicians with reliable tools.

Hologic, Inc. (HOLX) reported a fiscal Q4 2021 revenue of $1.317 billion, slightly below last year but exceeding expectations. GAAP diluted EPS was $1.28, down 31.9% year-over-year, while non-GAAP diluted EPS was $1.61, down 22.2%. The company anticipates solid growth in core women's health businesses for fiscal 2022, projecting revenues of $3.750B to $4.000B. Key highlights include a 47% annual revenue growth driven by women's health and COVID-19 testing, although COVID-19 assay sales decreased substantially. Strong operational cash flow of $465.4 million was reported for Q4.

Hologic, Inc. has launched the Aptima® SARS-CoV-2/Flu Assay for simultaneous detection of SARS-CoV-2, influenza A, and influenza B. The assay, CE-Marked for Europe and FDA authorized, provides results in approximately three hours and can process over 1,000 tests daily. This multiplex test addresses the overlap of symptoms between these viruses, enhancing testing options as the flu season approaches. Hologic has distributed over 100 million SARS-CoV-2 assays globally.

Hologic, Inc. has partnered with Mediflix to release Carolina, a documentary-style film highlighting the breast cancer journey. Launched during Breast Cancer Awareness Month, this film guides patients from diagnosis to reconstruction. Featuring testimonials from survivors and experts, Carolina aims to enhance understanding of minimally invasive surgical options, such as the Reconstructive Lumpectomy. This innovative approach uses Hologic’s BioZorb marker to improve cosmetic outcomes post-surgery, addressing the emotional concerns of patients.

Black Women’s Health Imperative and Hologic hosted a roundtable, Unmuting Fibroids: Getting Loud for Equal Care, addressing disparities in uterine fibroid care. Experts emphasized that understanding menstruation as a vital health sign is crucial for prioritizing care. Uterine fibroids affect 80% of Black women, leading to severe health implications. Key initiatives include improving education for healthcare providers, advocating for funding legislation, and promoting culturally competent care to reduce disparities. Hologic supports this through its Project Health Equality.

Hologic, Inc. (NASDAQ: HOLX) has announced the acquisition of Bolder Surgical for approximately $160 million. This strategic move aims to diversify Hologic's surgical portfolio by adding advanced vessel sealing devices. Bolder's products are expected to enhance surgical efficiency, particularly in OB/GYN applications, capitalizing on a larger market potential. The acquisition is forecasted to generate $10 million in revenue this year and is expected to be slightly dilutive to earnings in fiscal 2022, with a break-even outlook for fiscal 2023.

Hologic, Inc. (NASDAQ: HOLX) will release its fourth quarter fiscal 2021 financial results on Monday, November 1, after market close. A conference call hosted by management will take place at 4:30 p.m. ET. Interested participants can join by calling 800-458-4121 (US/Canada) or +1 323-794-2093 (international) with access code 2820462. A replay will be available post-call through December 1, 2021. Additionally, the call will be accessible via a live webcast on the company’s website at www.investors.hologic.com.

Hologic, Inc. has launched the Novodiag^® system across Europe, enhancing its molecular diagnostic solutions portfolio. This fully automated diagnostic tool tests for infectious diseases and antimicrobial resistance, following the acquisition of Mobidiag in June 2021. The Novodiag system utilizes real-time PCR and microarray technologies, allowing for rapid multiple pathogen identification from a single sample. It features a CE-IVD test menu for gastrointestinal infections and SARS-CoV-2 detection, with a strong pipeline of future assays.